Biosenic

Biosenic EBIT per Share

The EBIT per Share of Biosenic (BIOS.BR) as of Nov 4, 2026 is -0.02 EUR. In the previous year, EBIT per Share was -0.05 EUR — a change of -55.86% (higher).

EBIT per Share

-0.02EUR

YoY

-55.86%

Last updated:

EBIT per Share of Biosenic is 2024 -0.02 EUR. EBIT per Share of Biosenic was 2023 -0.05 EUR. It decreases by -55.86% higher compared to the previous year.

The Biosenic EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
-1.51 EUR
Jan 1, 2019
-0.83 EUR
Jan 1, 2020
-1.28 EUR
Jan 1, 2021
-0.71 EUR
Jan 1, 2022
-0.02 EUR
Jan 1, 2023
-0.05 EUR
Jan 1, 2024
-0.02 EUR
The Biosenic EBIT per Share history
YEAREBIT per ShareYoY
-0.02EUR-55.86%
-0.05EUR+164.80%
-0.02EUR-97.29%
-0.71EUR-44.32%
-1.28EUR+53.72%
-0.83EUR-44.71%
-1.51EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biosenic Stock analysis

What does Biosenic do? Bone Therapeutics SA is a Belgian company specializing in the development of innovative therapies for bone and joint diseases. Its goal is to treat patients with severe orthopedic conditions and help improve their quality of life. The company's business model is based on extensive research and development strategies aimed at developing groundbreaking therapies for diseases such as fractures, osteoporosis, osteoarthritis, and other bone and joint-related conditions. It focuses on the development of innovative stem cell-based therapies that help repair damaged tissues and promote self-regeneration. Additionally, Bone Therapeutics has developed a special cell therapy called Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells, targeting cartilage growth as an alternative, cell-based therapy for knee and hip osteoarthritis. It has also developed a platform called Allogeneic Osteoblastic Cells, aiming to treat ligament and tendon injuries. The company conducts research and clinical studies in collaboration with academic partners to improve its therapies and develop new products and solutions. It operates in three business areas: Orthobiology, Cardiology, and Immunology, focusing on the development and marketing of therapies for bone and joint arthritis, cardiovascular diseases, and autoimmune diseases, respectively. Its current product offerings include Allob, AlgoScaff, and JTA-004 for the treatment of orthopedic conditions such as fractured vertebrae, severe bone injuries, bone regeneration, osteoporosis, and osteoarthritis. Bone Therapeutics is headquartered in Gosselies, Belgium, with offices in the US, France, Germany, and Italy. Its mission is to advance the development of therapies for bone and joint diseases and assist patients with severe orthopedic conditions. Through its research and development strategies, collaboration with academic partners, and strong market position, Bone Therapeutics aims to make a difference in the field. Biosenic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biosenic stock

EBIT per Share of Biosenic is -0.02 EUR in 2024.

EBIT per Share of Biosenic changed from -0.05 EUR to -0.02 EUR, representing a -55.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Biosenic since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Biosenic

All Key Metrics — Biosenic